Development and In Vitro Characterization of Milk-Derived Extracellular Vesicle-Mithramycin Formulations for Potential Glioma Therapy.
Sign Up to like & getrecommendations! Published in 2025 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.4c01189
Abstract: Glioblastoma (GBM) is a highly aggressive brain tumor with resistance to conventional therapies. Mithramycin (Mit-A), a potent antitumor agent, has shown promise in several tumor types including, GBM. However, its clinical application is limited by… read more here.
Keywords: mev mit; mit; milk derived; derived extracellular ... See more keywords